Department of Pharmacy, School of Medical and Allied Sciences, Galgotias University, Greater Noida, Uttar Pradesh, India.
Institute of Pharmaceutical Research, GLA University, Mathura, India.
Curr Pharm Des. 2023;29(35):2802-2813. doi: 10.2174/0113816128274618231105173031.
Alzheimer's disease (AD) is a complicated, multifaceted, irreversible, and incurable neurotoxic old age illness. Although NMDA (N-methyl D-aspartate)-receptor antagonists, cholinesterase repressors, and their pairings have been approved for the treatment, they are useful for short symptomatic relief. Researchers throughout the globe have been constantly working to uncover the therapy of Alzheimer's disease as new candidates must be determined, and newer treatment medicines must be developed. The aim of this review is to address recent advances in medication research along with new Alzheimer's disease therapy for diverse targets. Information was gathered utilizing a variety of internet resources as well as websites, such as ALZFORUM (alzforum.org) and clinicaltrials.gov. In contrast to other domains, the proposed medicines target amyloids (secretases, A42 generation, neuroinflammation, amyloid precipitation, and immunization), tau proteins (tau phosphorylation/aggregation and immunotherapy), and amyloid deposition. Despite tremendous advancement in our understanding of the underlying pathophysiology of Alzheimer's disease, the FDA (Food and Drug Administration) only approved aducanumab for diagnosis and treatment in 2003. Hence, novel treatment tactics are needed to find and develop therapeutic medicines to combat Alzheimer's disease.
阿尔茨海默病（AD）是一种复杂、多方面的、不可逆转的、无法治愈的神经毒性老年病。虽然 NMDA（N-甲基-D-天冬氨酸）-受体拮抗剂和胆碱酯酶抑制剂及其组合已被批准用于治疗，但它们仅对短期症状缓解有效。全球的研究人员一直在努力寻找治疗阿尔茨海默病的方法，因为必须确定新的候选药物，并且必须开发新的治疗药物。本综述的目的是讨论药物研究的最新进展以及针对不同靶点的新的阿尔茨海默病治疗方法。信息是通过各种互联网资源以及网站（如 ALZFORUM（alzforum.org）和 clinicaltrials.gov）收集的。与其他领域不同，拟议的药物针对淀粉样蛋白（分泌酶、A42 生成、神经炎症、淀粉样蛋白沉淀和免疫接种）、tau 蛋白（tau 磷酸化/聚集和免疫疗法）和淀粉样蛋白沉积。尽管我们对阿尔茨海默病的潜在病理生理学有了巨大的理解，但 FDA（食品和药物管理局）仅在 2003 年批准 aducanumab 用于诊断和治疗。因此，需要新的治疗策略来寻找和开发治疗阿尔茨海默病的药物。
